Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

NCT01427244 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Paget's Disease of the Vulva

Interventions

DRUG: trastuzumab

Sponsor

Yale University

Collaborators

[object Object]